These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7164015)

  • 1. Inhibition of activated coagulation factor VII by normal human plasma.
    Dahl PE; Abildgaard U; Larsen ML; Tjensvoll L
    Thromb Haemost; 1982 Dec; 48(3):253-6. PubMed ID: 7164015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities.
    Chang YJ; Hamaguchi N; Chang SC; Ruf W; Shen MC; Lin SW
    Biochemistry; 1999 Aug; 38(34):10940-8. PubMed ID: 10460149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitor of F VIIa in plasma measured with a sensitive chromogenic substrate assay: comparison with antithrombin, protein C and heparin cofactor II in a clinical material.
    Abildgaard U; Sandset PM; Andersson TR; Odegaard OR; Rosĕn S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(3):274-7. PubMed ID: 2465215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.
    Lormeau JC; Herault JP; Herbert JM
    Thromb Haemost; 1996 Jul; 76(1):5-8. PubMed ID: 8819242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
    Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
    Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X.
    Osterud B; Miller-Andersson M; Abildgaard U; Prydz H
    Thromb Haemost; 1976 Apr; 35(2):295-304. PubMed ID: 61631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol.
    Sandset PM; Larsen ML; Abildgaard U; Lindahl AK; Odegaard OR
    Blood Coagul Fibrinolysis; 1991 Jun; 2(3):425-33. PubMed ID: 1932528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action.
    Broze GJ; Warren LA; Novotny WF; Higuchi DA; Girard JJ; Miletich JP
    Blood; 1988 Feb; 71(2):335-43. PubMed ID: 3422166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII.
    Iino M; Foster DC; Kisiel W
    Arch Biochem Biophys; 1998 Apr; 352(2):182-92. PubMed ID: 9587405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting the interaction of tissue factor/factor VII with factor X in a heterogeneous tubular reactor.
    Gemmell CH; Turitto VT; Nemerson Y
    Thromb Haemost; 1991 Feb; 65(2):139-43. PubMed ID: 2053099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, purification, and characterization of recombinant human factor X.
    Rudolph AE; Mullane MP; Porche-Sorbet R; Miletich JP
    Protein Expr Purif; 1997 Aug; 10(3):373-8. PubMed ID: 9268685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma tissue factor plus activated peripheral mononuclear cells activate factors VII and X in cardiac surgical wounds.
    Hattori T; Khan MM; Colman RW; Edmunds LH
    J Am Coll Cardiol; 2005 Aug; 46(4):707-13. PubMed ID: 16098440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedures for the isolation and characterization of human antithrombin III].
    Trobisch H; Wüst T; Rustige H
    Behring Inst Mitt; 1986 Feb; (79):177-90. PubMed ID: 3718405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with chromogenic substrates in studies of clotting and fibrinolytic systems.
    Chmielewska J; Latallo ZS
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):111-4. PubMed ID: 6177591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.
    Rao LV; Rapaport SI
    Blood; 1987 Feb; 69(2):645-51. PubMed ID: 3492226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization with a simple clotting assay of the tissue factor inhibiting activity in serum.
    Cassetti M; Minestrini D; Palazzesi G
    Haematologica; 1990; 75(1):32-7. PubMed ID: 2242114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.